Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk.

Mannucci, E; Rotella, C M

Mannucci, E; Rotella, C M.

Affiliation

Mannucci E; Geriatric Unit, University of Florence, Florence, Italy. edoardo.mannucci@unifi.it

Nutr Metab Cardiovasc Dis ; 18(9): 639-45, 2008 Nov.

Article in En | MEDLINE | ID: mdl-18849155

Subject(s)

Cardiovascular Diseases/prevention & control; Diabetes Mellitus, Type 2/drug therapy; Glucagon-Like Peptide 1/pharmacology; Blood Pressure/drug effects; Body Weight/drug effects; Cardiovascular Diseases/etiology; Diabetes Mellitus, Type 2/complications; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Glucagon-Like Peptide 1/therapeutic use; Heart Rate/drug effects; Humans; Incretins/therapeutic use; Insulin Resistance; Myocardial Contraction/drug effects; Myocardial Ischemia/prevention & control; Risk Factors

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 2_ODS3 Database: MEDLINE Main subject: Cardiovascular Diseases / Diabetes Mellitus, Type 2 / Glucagon-Like Peptide 1 Type of study: Etiology_studies Limits: Humans Language: En Journal: Nutr Metab Cardiovasc Dis Year: 2008 Document type: Article

Fulltext

XML

PubMed Links

Search on Google